Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients
Bertrand Baujat; Hélène Audry; Jean Bourhis; Anthony T. C. Chan; Haluk Onat; Daniel T. T. Chua; Dora L.W. Kwong; Muhyi Al-Sarraf; Kwan-Hwa Chi; et al. (Profiled Authors: Anthony Tak-cheung Chan; Sing-fai Leung)
International Journal of Radiation Oncology Biology Physics. 2006;64(1):47-56.Abstract
Objectives: To study the effect of adding chemotherapy to radiotherapy (RT) on overall survival and event-free survival for patients with nasopharyngeal carcinoma. Methods and Materials: This meta-analysis used updated individual patient data from randomized trials comparing chemotherapy plus RT with RT alone in locally advanced nasopharyngeal carcinoma. The log-rank test, stratified by trial, was used for comparisons, and the hazard ratios of death and failure were calculated. Results: Eight trials with 1753 patients were included. One trial with a 2 × 2 design was counted twice in the analysis. The analysis included 11 comparisons using the data from 1975 patients. The median follow-up was 6 years. The pooled hazard ratio of death was 0.82 (95% confidence interval, 0.71-0.94; p = 0.006), corresponding to an absolute survival benefit of 6% at 5 years from the addition of chemotherapy (from 56% to 62%). The pooled hazard ratio of tumor failure or death was 0.76 (95% confidence interval, 0.67-0.86; p < 0.0001), corresponding to an absolute event-free survival benefit of 10% at 5 years from the addition of chemotherapy (from 42% to 52%). A significant interaction was observed between the timing of chemotherapy and overall survival (p = 0.005), explaining the heterogeneity observed in the treatment effect (p = 0.03), with the highest benefit resulting from concomitant chemotherapy. Conclusion: Chemotherapy led to a small, but significant, benefit for overall survival and event-free survival. This benefit was essentially observed when chemotherapy was administered concomitantly with RT. © 2006 Elsevier Inc.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Ravi D. Rao; Sunil Krishnan; Tom R. Fitch; Paula J. Schomberg; Robert P. Dinapoli; Kathleen Nordstrom; Bernd Scheithauer; Judith R. O'Fallon; Matthew J. Maurer; et al.
Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): Results of North Central Cancer Treatment Group trial 98-72-51International Journal of Radiation Oncology Biology Physics. 2005;61(2):380-386.
Ritsuko Komaki; R. Suzanne Swann; David S. Ettinger; Bonnie S. Glisson; Alan B. Sandler; Benjamin Movsas; John Suh; Roger W. ByhardtInternational Journal of Radiation Oncology Biology Physics. 2005;62(2):342-350.
Daniel T.T. Chua; Jun Ma; Jonathan S.T. Sham; Hai-Qiang Mai; Damon T.K. Choy; Ming-Huang Hong; Tai-Xiang Lu; Gordon K.H. Au; Hua-Qing MinInternational Journal of Radiation Oncology Biology Physics. 2006;65(5):1300-1306.
Appears in this Document